Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been given a consensus rating of “Moderate Buy” by the eleven research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $131.30.

ORKA has been the subject of several recent analyst reports. UBS Group increased their price objective on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. BTIG Research reiterated a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a report on Thursday, May 14th. Piper Sandler reiterated an “overweight” rating and issued a $180.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Guggenheim set a $200.00 target price on Oruka Therapeutics and gave the company a “buy” rating in a research note on Monday, April 27th. Finally, Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th.

Insider Buying and Selling at Oruka Therapeutics

In related news, CEO Lawrence Otto Klein sold 1,729 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $69.69, for a total value of $120,494.01. Following the completion of the transaction, the chief executive officer owned 925,580 shares of the company’s stock, valued at approximately $64,503,670.20. This trade represents a 0.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Arjun Agarwal sold 1,587 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $80.95, for a total transaction of $128,467.65. Following the completion of the transaction, the senior vice president directly owned 15,312 shares of the company’s stock, valued at $1,239,506.40. This represents a 9.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 185,407 shares of company stock valued at $11,636,307. 23.49% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ORKA. Viking Global Investors LP acquired a new position in Oruka Therapeutics in the 3rd quarter worth approximately $51,280,000. Paradigm Biocapital Advisors LP acquired a new stake in Oruka Therapeutics during the 4th quarter worth about $51,840,000. Remedium Capital Partners LLC acquired a new stake in Oruka Therapeutics during the 4th quarter worth about $47,054,000. Avoro Capital Advisors LLC acquired a new stake in Oruka Therapeutics during the 3rd quarter worth about $25,640,000. Finally, Deep Track Capital LP boosted its position in Oruka Therapeutics by 38.4% during the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after acquiring an additional 735,983 shares during the period. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Stock Performance

NASDAQ:ORKA opened at $92.49 on Tuesday. Oruka Therapeutics has a 1 year low of $10.97 and a 1 year high of $95.38. The stock has a market cap of $5.58 billion, a price-to-earnings ratio of -47.68 and a beta of -0.25. The business has a fifty day moving average of $67.46 and a 200-day moving average of $47.87.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.04. On average, equities research analysts predict that Oruka Therapeutics will post -2.06 EPS for the current year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.